Traders should note the stock has already converged to near the $25.00 deal price (closed at $25.00 on June 8, 2026), indicating minimal arbitrage spread. The primary risk is deal completion — focus on regulatory approvals from the Required Government Authorities (Belgium, Sweden, Australia, Saudi Arabia, Mexico, Canada) and the HSR waiting period. If the stock trades below $25.00, the spread reflects execution risk rather than valuation uncertainty. Monitor for any competing Superior Proposal triggering the 4-business-day go-shop match period.
Price Chart
Executive Summary
Avanos Medical enters a definitive agreement to be acquired by American Industrial Partners (AIP) for $25.00 per share in cash, representing a 72% premium to the last unaffected closing price of $14.53. The all-cash deal values Avanos at approximately $1.17 billion in equity value, with total required funds of ~$1.42 billion including debt repayment and equity award settlements. The board unanimously recommends approval; a special stockholder vote is set for July 22, 2026.
Key Financial Metrics
Key Facts
- Merger consideration: $25.00 per share in cash, no stock component or CVR
- Premium of ~72% based on $14.53 closing price on April 13, 2026 (last pre-announcement trading day)
- Equity commitment of $1.4 billion from AIP Fund; no financing condition for Parent
- Total required funds for the deal: ~$1.42 billion including debt repayment and equity award settlements
- Board of Directors unanimous recommendation FOR the merger proposal
- Special meeting scheduled for July 22, 2026; record date June 18, 2026
- J.P. Morgan issued fairness opinion that $25.00 per share is fair from a financial point of view
- Approval requires majority of outstanding shares; abstentions and failures to vote count as AGAINST
- Appraisal rights available under DGCL Section 262 for dissenting stockholders
- Termination fee payable by Avanos: $37.5 million in certain circumstances
- Closing expected in second half of 2026, subject to regulatory approvals (HSR, multiple foreign jurisdictions) and stockholder vote
- Directors and executive officers holding ~0.35% of outstanding shares expected to vote in favor
Financial Impact
$25.00 per share in cash, ~72% premium to unaffected price of $14.53, total equity value ~$1.17B based on 46.85M shares outstanding
Risk Factors
- Regulatory delays or failure to obtain Required Regulatory Approvals (multiple foreign jurisdictions)
- Antitrust challenge in any of the six Required Government Authority countries
- Stockholder vote failure: abstentions and non-votes count as AGAINST, requiring majority of all outstanding shares
- Material Adverse Effect clause could allow termination if Avanos business deteriorates significantly
- Litigation risk: though none filed as of proxy date, deal-related lawsuits are common
- Termination fee of $37.5M is not large relative to deal value (~3.2%) but could deter competing bidders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001104659-26-072432 |
| Document: tm2614353-2_defm14a.htm | 0001104659-26-072432 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 27, 2026 9w ago | 25-NSE | $24.99 awaiting T+5 | awaiting T+5 | — | — |
Jul 2, 2026 13w ago | 8-K / DEFA14A | $24.93 $24.94 | ▲ +0.04% | ▼ −0.89% | — |
Jun 10, 2026 16w ago | DEFM14A | $24.98 $24.87 | ▼ −0.44% | ▼ −0.87% | — |
May 5, 2026 21w ago | DEFA14A | $24.72 $24.73 | ▲ +0.04% | ▼ −1.09% | — |
Apr 23, 2026 23w ago | DEFA14A | $24.71 $24.65 | ▼ −0.24% | ▼ −1.72% | — |
Apr 14, 2026 24w ago | DEFA14A | $24.63 $24.64 | ▲ +0.04% | ▼ −1.35% | — |
Feb 26, 2026 31w ago | 8-K | $14.49 $13.79 | ▼ −4.83% | ▼ −3.70% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access